ancrod


Also found in: Wikipedia.

ancrod

 [ang´krod]
a proteinase obtained from the venom of the Malayan pit viper Agkistrodon rhodostoma, acting specifically on fibrinogen; used as an anticoagulant in the treatment of retinal vein occlusion and deep vein thrombosis and to prevent postoperative rethrombosis.

an·crod

(an'krod),
A fraction obtained from the venom of the Malayan pit viper, Agkistrodon rhodostoma, which contains a fibrinogen-splitting enzyme; produces hypofibrinogenemia and diminution of both whole blood and plasma viscosity for improvement of the rheologic properties of blood, and is used in treatment of chronic peripheral vascular disease.

ancrod

[ang′krod]
the venom of the Malayan pit viper, used to remove fibrinogen from the circulation, to prevent blood clotting. Also called Malayan pit viper venom.

ancrod

A protease occurring in the venom of the Malaysian pit viper Agkistrodon rhodostoma . The enzyme removes fibrinogen from the circulating blood without converting it to fibrin. It does not cause platelet aggregation and is used by Chinese doctors to treat STROKE. Trials have suggested that it should not be used after the first three hours.
References in periodicals archive ?
Randomized controlled trials of acute reduction in plasma fibrinogen with a defibrinating snake venom enzyme, ancrod, have shown reductions in the risk for venous thromboembolism in surgical and stroke patients and a reduction in cerebral infarct size in acute ischemic stroke (6); however, the benefit of the latter effect was outweighed by an increased risk of intracranial bleeding.
Heparine bagli trombositopeni gelisen hastalarda KPB sirasinda antikoagulasyon icin danaparoid, ancrod ve recombinant hirudin tercih edilebilir.
NTI) (Nasdaq: NTII) announced today the presentation of new analysis of data from prior clinical trials of ancrod and updates on the clinical development of their investigational drug, Viprinex(TM) (ancrod), for the treatment of acute ischaemic stroke at the 16th annual European Stroke Congress in Glasgow, Scotland in the United Kingdom.
Viprinex (Ancrod) is currently being studied in two Phase III global trials known as Ancrod Stroke Program I (ASP-I) and Ancrod Stroke Program II (ASP-II).
Key members of the Nordmark team produced the product while employed by the former Knoll AG, the previous manufacturer of ancrod.
One trial of 500 patients reached statistical significance for improved outcome when ancrod was started within 3 hours of symptom onset, and larger trials in Europe and China are planned.
Ancrod is less likely to cause internal bleeding than existing drugs and it can also protect against further strokes, by lowering levels of clotting substances in the blood.
8,34,97] On the basis of these disappointing results, new approaches have been proposed that have included the use of LMWH, heparinoids, anticoagulating agents such as ancrod, prostaglandin (Iloprost), antiplatelet drugs, and thrombin inhibitors (argatroban and hirudin).
In a study of 500 stroke patients, 42percent who were given the drug ancrod within three hours regained significant functioning.
TPA may be more effective, but ANCROD may have fewer bleeding complications.
Ancrod has been approved for use in Canada for treatment of phlebitis.
Other options include ancrod (snake venom with antifibrinolytic activity), danaparoid (heparin, chrondroitin, and dermatan), and plasmapheresis.